Correction for: PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer

Aging (Albany NY). 2024 Dec 31;16(22):13693. doi: 10.18632/aging.206186. Online ahead of print.

Authors

Zhixuan Ren¹, Li Wang², Chaohui Leng³

Affiliations

¹ Department of Radiation Oncology, Huadong Hospital, Fudan University, Shanghai 200433, P.R. China.
² Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, P.R. China.
³ Department of Oncology, Jiujiang University Affiliated Hospital, Jiujiang 332000, P.R. China.

PMID: 39760523
DOI: 10.18632/aging.206186

No abstract available

Keywords: NSCLC; PTPRD; TCGA; immune checkpoint inhibitors; nomogram.

Publication types

Published Erratum